Casey Mark J 4/A

What Happened
Mark J. Casey, Executive Vice President and Chief Legal Officer of Novavax, was granted a 152,000-share derivative award (reported as an option/award) on March 2, 2026. The filing shows the award in Table II as 152,000 shares at $0.00 (derivative), and the Form 4/A filed March 9, 2026 amends the exercise price / price information previously reported on March 3, 2026. This is a grant (not a sale) and does not by itself signal a buy or sell decision by the insider.

Key Details

• Transaction date: 2026-03-02 (reported on Form 4 filed March 3; amended Form 4/A filed March 9, 2026).
• Transaction type: Grant / award of a derivative security (reported as 152,000 shares @ $0.00).
• Vesting: 1/4 vests on the first anniversary of March 2, 2026; remaining 3/4 vest in equal monthly installments over the following 3 years, subject to continued employment.
• Amendment: Footnote states this Form 4/A was filed solely to amend the exercise price and price of the derivative security from the March 3 filing.
• Shares owned after transaction: Not specified in the provided extract; see the full Form 4/A for post-transaction holdings.
• Timeliness: Initial report was filed promptly (March 3); this filing is an amendment correcting price details.

Context
This was an equity award/option grant with a multi-year vesting schedule—common for executive compensation and retention. Because it is a grant (not an open-market purchase or sale), it should be viewed as part of standard compensation practice rather than a direct insider market signal. Check the full amended Form 4 for the corrected exercise price and the reporting of total holdings if you need complete ownership details.